A 24-week multicenter, randomized, double-blind, parallel-group, dose-ranging study of rufinamide in adults and adolescents with inadequately controlled partial seizures

SummaryObjectiveTo assess the efficacy, safety, tolerability, and pharmacokinetics of adjunctive rufinamide in adults and adolescents with inadequately controlled partial seizures receiving treatment with one to three concomitant antiepileptic drugs (AEDs).MethodsA 24-week multicenter Phase II clinical study was conducted (n = 647), comprising a 12-week prospective baseline phase and a 12-week randomized double-blind, parallel-group, five-arm (placebo and rufinamide 200, 400, 800, and 1600 mg/day) treatment phase.ResultsThe linear trend of dose response for seizure frequency per 28 days in the double-blind treatment phase – the primary efficacy outcome measure – was statistically significant in favor of rufinamide (estimated slope = −0.049, P = 0.003; minimally efficacious dose, 400 mg/day). Response rates, defined as a ≥50% reduction in seizure frequency per 28 days, also revealed a significant linear trend of dose response (P = 0.0019, logistic regression analysis). Adverse events were comparable between placebo and all rufinamide groups except the 1600 mg/day group; no safety signals were observed.ConclusionsThese results suggest that in the dose range of 400–1600 mg/day, add-on rufinamide therapy may benefit patients with inadequately controlled partial seizures and is generally well tolerated. These data also suggest that higher doses may confer additional efficacy without adversely affecting safety and tolerability.